For the Inventor, By the Inventor

Enter assignee name

New Haven, CT, United States of America

Arvinas Operations, Inc.

USPTO Granted Patents = 67

EPO Patents = 7

Trademarks = 4

Forward Citations = 157

Loading Chart...

Loading Chart...

42 inventors (with patents filed for the assignee):

Andrew Philip Crew (46 out of 78 patents)

Jing Wang (44 out of 58 patents)

Hanqing Dong (43 out of 57 patents)

4. Yimin Qian (28 out of 73 patents)

5. Michael Berlin (23 out of 45 patents)

6. Lawrence B Snyder (17 out of 47 patents)

7. Keith R Hornberger (17 out of 19 patents)

8. Craig M Crews (14 out of 34 patents)

9. Kurt Zimmermann (10 out of 27 patents)

10. Steven M Sparks (8 out of 8 patents)

11. Xin Chen (6 out of 17 patents)

12. Wei Zhang (6 out of 6 patents)

13. Saul Jaime-Figueroa (4 out of 11 patents)

14. Erika Araujo (4 out of 4 patents)

15. Meizhong Jin (4 out of 25 patents)

Core Competencies:

Androgen Receptor

LRRK2

Estrogen Receptor

Proteolysis

PROTAC

BCL6

Fibrosarcoma

Modulators

Cereblon

Tau-Protein

Interleukin-1

Bromodomain

67 patents: Sort by Forward Citations

1. 12760003 - Modulators of BCL6 proteolysis and associated methods of use (2026-10-13),

2. 12594264 - Modulators of alpha-synuclein proteolysis and associated methods of use (2026-04-07),

3. 12589156 - Benzimidazole and benzimidazolone based protac compounds for the targeted degradation of leucine rich repeat kinase 2 (LRRK2) (2026-03-31),

4. 12577255 - MDM2-based modulators of proteolysis and associated methods of use (2026-03-17),

5. 12569464 - Protein-protein interaction inducing technology (2026-03-10),

6. 12559506 - Indazole based compounds and associated methods of use (2026-02-24),

7. 12559486 - Tau-protein targeting compounds and associated methods of use (2026-02-24),

8. 12552783 - Modulators of proteolysis and associated methods of use (2026-02-17),

9. 12539292 - BRM targeting compounds and associated methods of use (2026-02-03),

10. 12496301 - USE OF ANDROGEN RECEPTOR DEGRADER FOR THE TREATMENT OF SPINAL AND BULBAR MUSCULAR ATROPHY (2025-12-16),

11. 12473294 - Selective modulators of mutant LRRK2 proteolysis and associated methods of use (2025-11-18),

12. 12448399 - Cereblon-based KRAS degrading PROTACs and uses related thereto (2025-10-21),

13. 12441708 - Cereblon ligands and bifunctional compounds comprising the same (2025-10-14),

14. 12427144 - Compounds and methods for the targeted degradation of androgen receptor (2025-09-30),

15. 12419960 - Compounds and methods for the targeted degradation of androgen receptor and associated methods of use (2025-09-23),

Company Overview

Arvinas Operations, Inc., based in New Haven, CT, specializes in the innovative field of targeted protein degradation. The company focuses on developing therapies that harness the body's natural proteolytic systems to selectively degrade disease-causing proteins. Their core technologies include PROTACs (Proteolysis Targeting Chimeras) and various modulators targeting critical proteins such as the androgen receptor, estrogen receptor, and LRRK2. Arvinas is dedicated to advancing treatments for conditions like fibrosarcoma and other serious diseases.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

67 Patents

#6 in New Haven, CT

#151 in Connecticut

#5,458 in US

#11,031 in the World

New Haven, CT, United States of America

Arvinas Operations, Inc.

Forward Citations = 157

42 inventors:

Andrew Philip Crew (46 out of 78 patents)

Jing Wang (44 out of 58 patents)

Hanqing Dong (43 out of 57 patents)

4. Yimin Qian (28 out of 73 patents)

5. Michael Berlin (23 out of 45 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Arvinas Operations, Inc.. Retrieved from https://idiyas.com/company/arvinas-operations

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…